Related coverage linked through entity extraction aliases.
May 26, 2026
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
Apr 25, 2026
Alvotech said it will release first-quarter 2026 financial results on May 6, 2026, and host a webcast with live Q&A on May 7. The company said five biosimilars are already approved and marketed, with nine disclosed candidates in development.
Apr 24, 2026
The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.
Apr 24, 2026
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Apr 17, 2026
The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion to USD 5.73 billion by 2035 at a 19% CAGR. Monoclonal antibodies hold almost 55% of market share, while oncological disorders dominate demand.
Apr 17, 2026
Europe's infusion pump market is projected to reach USD 7.09 billion by 2031 at a 6.8% CAGR. Growth is driven by connected systems, tighter safety standards, homecare use, and diabetes demand.
Apr 14, 2026
Virginia lawmakers are again advancing a Prescription Drug Affordability Board bill, while Gov. Abigail Spanberger seeks amendments. The measure would create a board to analyze drug pricing and apply federal caps to state-regulated plans.
Apr 02, 2026
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
Apr 01, 2026
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Mar 23, 2026
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
Mar 17, 2026
Prognica Labs and NextGen Immuno Therapeutics announced a strategic partnership to advance AI-powered immune diagnostics and personalized medicine across the GCC, India, and the United States, targeting oncology, transplant medicine, and autoimmune disorders.
Mar 12, 2026
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Mar 11, 2026
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
Feb 26, 2026
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
Feb 16, 2026
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
Feb 13, 2026
Immunotherapy is increasingly being used before and after surgery across seven cancer types, while the global immunotherapy drugs market experiences significant growth driven by advances in biotechnology and targeted therapies.
